Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 2016. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMRs), or connected persons, in accordance with DTR 3.1.4 R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes and Transactions
The filing details an increase in the notional allocation of GSK American Depositary Shares (ADSs) within the GSK 401(K) plan. This adjustment occurred on January 29, 2016, following the revaluation of the cash element of the notional investment.
- Transaction Price: $41.29 per ADS.
- Director/PDMR: Dr. M M Slaoui received an allocation of 26 ADSs.
- Connected Person: Dr. K Slaoui (connected to Dr. M M Slaoui) received an allocation of 9 ADSs.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the specific share allocations described above.
Investor Verification Checklist
- Verify the total number of ADSs allocated to Dr. M M Slaoui and Dr. K Slaoui (26 and 9, respectively).
- Confirm the transaction price of $41.29 per ADS used for the revaluation on January 29, 2016.
- Ensure these allocations are consistent with the rules of the GSK 401(K) plan regarding notional investment revaluations.